Thursday, April 22, 2010

More JACC Analysis of Arbiter 6-HALTS, From A Commenter

This anonymous comment deserves top-of-page mention:

. . . .More interesting stuff from the ARBITER-6 paper just published in JACC. Figure 1 tells a huge story! Shows that the greater the exposure (measured by the product of dose/day, adherence, and time on therapy) to ezetimibe, the more atherosclerosis progresses -- and the the greater the exposure to niacin, the more athero regresses. This is very damning for ezetimibe, as it takes any sidebar question of relationship to lipids, etc out of the equation, and just simply describes what happens the more drug exposure over time you have.

Does anyone else find it odd that Merck is so silent on this new publication? Quite the contrast from the Merck PR spin blitzkrieg back in November. C'mon Dick, where's that NYT letter-to-the editor about this new paper??? Peter Kim??? Dick Clark??? All you other shills on the Merck gravy train??? This is a material development in the Zetia/Vytorin story. . . .

-- Anonymous

April 22, 2010 @ 8:48 AM


1 comment:

Anonymous said...

Deja Vu!

Toxicity related to extent and duration of exposure.

Wow this sure reminds me of something. I think it's Vioxx.

Wait it's reminding me of something else. I think it's Saphris (asenapine).

Don't ya ever wonder why Pharma negotiated long term safety studies with ICH back in the early 90's of only 500 patients for 6 months and 100 patients for 1 year at the lowest approved dose.

(N.B. with these numbers you can only say that the death rate within 6 months of beginning treatment is less than 1 in 167 people and within 1 year is less than 1 in 33 people.)

Of course this was after clozapine and during the during the development of Zyprexa and Risperdal.